Can-Fite BioPharma (CANF) Earnings Date, Estimates & Call Transcripts $1.96 -0.03 (-1.51%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends Get Can-Fite BioPharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Can-Fite BioPharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCANF Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CANF Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Can-Fite BioPharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ3 20241-$0.27-$0.27-$0.27Q4 20241-$0.24-$0.24-$0.24 Can-Fite BioPharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks3/28/2024Q4 2023-$0.27-$0.31 -$0.04-$0.31$0.20M$0.16M11/30/2023Q3 2023-$0.43-$0.43--$0.43$0.20M$0.20M8/31/2023Q2 2023-$0.54-$0.40+$0.14-$0.40$0.20M$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M Get the Latest News and Ratings for CANF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. 6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20MThere is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M11/25/2022Q3 2022-$1.00-$0.90+$0.10-$0.90$0.40M$0.20M Can-Fite BioPharma Earnings - Frequently Asked Questions How much revenue does Can-Fite BioPharma generate each year? Can-Fite BioPharma (NYSE:CANF) has a recorded annual revenue of $667,000.00. How much profit does Can-Fite BioPharma generate each year? Can-Fite BioPharma (NYSE:CANF) has a recorded net income of -$7.63 million. CANF has generated -$1.79 earnings per share over the last four quarters. What is Can-Fite BioPharma's EPS forecast for next year? Can-Fite BioPharma's earnings are expected to grow from ($1.25) per share to ($0.05) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies INKT Earnings NAII Earnings ICCC Earnings BTAI Earnings RNXT Earnings ENLV Earnings EQ Earnings ESLA Earnings GLYC Earnings TPST Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. This page (NYSE:CANF) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
